Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

Felipe Samaniego, Fredrick Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter Mclaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Younes, Lei Feng, Zuzana Berkova, Tamer Khashab, Lalit Sehgal, Francisco Vega, Larry W. Kwak

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Summary: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83% [95% confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.

Original languageEnglish (US)
Pages (from-to)814-823
Number of pages10
JournalBritish Journal of Haematology
Volume169
Issue number6
DOIs
StatePublished - Jun 1 2015
Externally publishedYes

Fingerprint

Pentostatin
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Cyclophosphamide
Confidence Intervals
Disease-Free Survival
Survival Rate
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Neutropenia
Lymphoma
Drug Therapy
Rituximab
Therapeutics

Keywords

  • Cyclophosphamide
  • Deoxycoformycin
  • Follicular lymphoma
  • Marginal zone lymphoma
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Samaniego, F., Hagemeister, F., Romaguera, J. E., Fanale, M. A., Pro, B., Mclaughlin, P., ... Kwak, L. W. (2015). Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. British Journal of Haematology, 169(6), 814-823. https://doi.org/10.1111/bjh.13367

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. / Samaniego, Felipe; Hagemeister, Fredrick; Romaguera, Jorge E.; Fanale, Michelle A.; Pro, Barbara; Mclaughlin, Peter; Rodriguez, M. Alma; Neelapu, Sattva S.; Fayad, Luis; Younes, Anas; Feng, Lei; Berkova, Zuzana; Khashab, Tamer; Sehgal, Lalit; Vega, Francisco; Kwak, Larry W.

In: British Journal of Haematology, Vol. 169, No. 6, 01.06.2015, p. 814-823.

Research output: Contribution to journalArticle

Samaniego, F, Hagemeister, F, Romaguera, JE, Fanale, MA, Pro, B, Mclaughlin, P, Rodriguez, MA, Neelapu, SS, Fayad, L, Younes, A, Feng, L, Berkova, Z, Khashab, T, Sehgal, L, Vega, F & Kwak, LW 2015, 'Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas', British Journal of Haematology, vol. 169, no. 6, pp. 814-823. https://doi.org/10.1111/bjh.13367
Samaniego, Felipe ; Hagemeister, Fredrick ; Romaguera, Jorge E. ; Fanale, Michelle A. ; Pro, Barbara ; Mclaughlin, Peter ; Rodriguez, M. Alma ; Neelapu, Sattva S. ; Fayad, Luis ; Younes, Anas ; Feng, Lei ; Berkova, Zuzana ; Khashab, Tamer ; Sehgal, Lalit ; Vega, Francisco ; Kwak, Larry W. / Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. In: British Journal of Haematology. 2015 ; Vol. 169, No. 6. pp. 814-823.
@article{9e4bfe0fd7424dcda539aaa534826a2e,
title = "Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas",
abstract = "Summary: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6{\%} attained an overall response and 86·8{\%} a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73{\%} and 93{\%}, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83{\%} [95{\%} confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73{\%} (95{\%} CI: 0·54, 1·0) for marginal zone lymphomas and 61{\%} (95{\%} CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13{\%} of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.",
keywords = "Cyclophosphamide, Deoxycoformycin, Follicular lymphoma, Marginal zone lymphoma, Small lymphocytic lymphoma",
author = "Felipe Samaniego and Fredrick Hagemeister and Romaguera, {Jorge E.} and Fanale, {Michelle A.} and Barbara Pro and Peter Mclaughlin and Rodriguez, {M. Alma} and Neelapu, {Sattva S.} and Luis Fayad and Anas Younes and Lei Feng and Zuzana Berkova and Tamer Khashab and Lalit Sehgal and Francisco Vega and Kwak, {Larry W.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/bjh.13367",
language = "English (US)",
volume = "169",
pages = "814--823",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas

AU - Samaniego, Felipe

AU - Hagemeister, Fredrick

AU - Romaguera, Jorge E.

AU - Fanale, Michelle A.

AU - Pro, Barbara

AU - Mclaughlin, Peter

AU - Rodriguez, M. Alma

AU - Neelapu, Sattva S.

AU - Fayad, Luis

AU - Younes, Anas

AU - Feng, Lei

AU - Berkova, Zuzana

AU - Khashab, Tamer

AU - Sehgal, Lalit

AU - Vega, Francisco

AU - Kwak, Larry W.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Summary: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83% [95% confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.

AB - Summary: We conducted a prospective phase II trial of pentostatin, cyclophosphamide and rituximab as initial therapy for patients with previously untreated advanced stage low-grade or indolent B-cell lymphomas (iNHLs). Of 83 evaluable patients, 91·6% attained an overall response and 86·8% a complete or unconfirmed complete response. The 3-year progression-free survival (PFS) and overall survival rates were 73% and 93%, respectively. The 3-year PFS rate was significantly different for different diagnoses (P = 0·01): 83% [95% confidence interval (CI): 0·72, 0·96] for follicular lymphomas, 73% (95% CI: 0·54, 1·0) for marginal zone lymphomas and 61% (95% CI: 0·46, 0·81) for small lymphocytic lymphomas. The most common adverse events were haematological. Of 509 cycles of chemotherapy administered, grade 3 or 4 neutropenia was reported in 68 cycles (13% of cycles administered) and most frequently occurred during cycles 4-6. This is the first report demonstrating the effectiveness of pentostatin, cyclophosphamide and rituximab in patients with previously untreated iNHLs, including those over 60 years of age.

KW - Cyclophosphamide

KW - Deoxycoformycin

KW - Follicular lymphoma

KW - Marginal zone lymphoma

KW - Small lymphocytic lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84930275510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930275510&partnerID=8YFLogxK

U2 - 10.1111/bjh.13367

DO - 10.1111/bjh.13367

M3 - Article

VL - 169

SP - 814

EP - 823

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -